

Table 1. Select Characteristics (n, column %) of the Pathways Study Cohort, by Race/Ethnicity							
	Enrolled (n, %)						Not Enrolled‡
	Asian/PI	Black	White	Hispanic*	AIAN	Total	n (%)
<b>Age Group (y)</b>							
<50	234 (39.1)	89 (25.4)	460 (15.6)	192 (37.5)	21 (22.8)	996 (22.1)	1364 (20.5)
50-59	199 (33.2)	125 (35.6)	805 (27.3)	163 (31.8)	24 (26.1)	1316 (29.2)	1747 (26.2)
60-69	121 (20.2)	91 (25.9)	966 (32.7)	90 (17.6)	29 (31.5)	1297 (28.8)	1824 (27.4)
≥70	45 (7.5)	46 (13.1)	720 (24.4)	67 (13.1)	18 (19.6)	896 (19.9)	1730 (26.0)
<b>Body Mass Index (kg/m<sup>2</sup>)§</b>							
<18.5	11 (1.8)	1 (0.3)	29 (1.0)	3 (0.6)	1 (1.1)	45 (1.0)	113 (1.7)
18.5-24	296 (49.4)	53 (15.1)	975 (33.0)	119 (23.2)	22 (23.9)	1465 (32.5)	1974 (29.6)
25-29	195 (32.6)	90 (25.6)	933 (31.6)	183 (35.7)	31 (33.7)	1432 (31.8)	2041 (30.6)
30-34	63 (10.5)	92 (26.2)	553 (18.7)	114 (22.3)	17 (18.5)	839 (18.6)	1172 (17.6)
≥35	34 (5.7)	115 (32.8)	460 (15.6)	93 (18.2)	21 (22.8)	723 (16.0)	915 (13.7)
Unknown	0 (0.0)	0 (0.0)	1 (0.0)	0 (0.0)	0 (0.0)	1 (0.0)	450 (6.8)
<b>Educational Attainment</b>							
High school or less	72 (12.0)	63 (17.9)	380 (12.9)	176 (34.4)	16 (17.4)	707 (15.7)	
Some college	116 (19.4)	160 (45.6)	1041 (35.3)	206 (40.2)	45 (48.9)	1568 (34.8)	
College graduate	282 (47.1)	78 (22.2)	781 (26.5)	83 (16.2)	17 (18.5)	1241 (27.5)	
Post-graduate	128 (21.4)	48 (13.7)	744 (25.2)	47 (9.2)	14 (15.2)	981 (21.8)	
Unknown	1 (0.2)	2 (0.6)	5 (0.2)	0 (0.0)	0 (0.0)	8 (0.2)	
<b>Household Income</b>							
<\$50K	140 (23.4)	132 (37.6)	814 (27.6)	166 (32.4)	26 (28.3)	1278 (28.4)	
\$50K-89K	145 (24.2)	105 (29.9)	840 (28.5)	161 (31.4)	30 (32.6)	1281 (28.4)	
≥\$90K	245 (40.9)	62 (17.7)	984 (33.3)	94 (18.4)	25 (27.2)	1410 (31.3)	
Unknown	69 (11.5)	52 (14.8)	313 (10.6)	91 (17.8)	11 (12.0)	536 (11.9)	
<b>AJCC Stage</b>							
I	318 (53.1)	163 (46.4)	1647 (55.8)	264 (51.6)	42 (45.7)	2434 (54.0)	3349 (50.2)
II	220 (36.7)	133 (37.9)	985 (33.4)	180 (35.2)	41 (44.6)	1559 (34.6)	2359 (35.4)
III	55 (9.2)	43 (12.3)	276 (9.4)	57 (11.1)	8 (8.7)	439 (9.7)	640 (9.6)
IV	6 (1.0)	12 (3.4)	43 (1.5)	11 (2.1)	1 (1.1)	73 (1.6)	255 (3.8)
<b>Nodal Status</b>							
Negative	413 (68.9)	225 (64.1)	2079 (70.5)	337 (65.8)	54 (58.7)	3108 (69.0)	4468 (67.0)
Positive	184 (30.7)	125 (35.6)	850 (28.8)	174 (34.0)	37 (40.2)	1370 (30.4)	2104 (31.6)
Unknown	2 (0.3)	1 (0.3)	22 (0.7)	1 (0.2)	1 (1.1)	27 (0.6)	93 (1.4)
<b>Metastases</b>							
No	592 (98.8)	335 (95.4)	2897 (98.2)	500 (97.7)	89 (96.7)	4413 (98.0)	6359 (95.4)
Yes	6 (1.0)	12 (3.4)	44 (1.5)	11 (2.1)	1 (1.1)	74 (1.6)	247 (3.7)
Unknown	1 (0.2)	4 (1.1)	10 (0.3)	1 (0.2)	2 (2.2)	18 (0.4)	59 (0.9)
<b>ER/PR Status</b>							
ER+, PR+	394 (65.8)	156 (44.4)	1942 (65.8)	315 (61.5)	47 (51.1)	2854 (63.4)	4175 (62.6)
ER+, PR-	106 (17.7)	74 (21.1)	584 (19.8)	107 (20.9)	25 (27.2)	896 (19.9)	1248 (18.7)
ER-, PR+	0 (0.0)	1 (0.3)	3 (0.1)	4 (0.8)	0 (0.0)	8 (0.2)	13 (0.2)
ER-, PR-	99 (16.5)	118 (33.6)	419 (14.2)	86 (16.8)	20 (21.7)	742 (16.5)	1205 (18.1)
Unknown	0 (0.0)	2 (0.6)	3 (0.1)	0 (0.0)	0 (0.0)	5 (0.1)	24 (0.4)
<b>HER-2/Neu Status</b>							
Positive	107 (17.9)	49 (14.0)	343 (11.6)	78 (15.2)	11 (12.0)	588 (13.1)	913 (13.7)
Negative	468 (78.1)	290 (82.6)	2489 (84.3)	407 (79.5)	76 (82.6)	3730 (82.8)	5679 (85.2)
Test Not Done	24 (4.0)	12 (3.4)	118 (4.0)	27 (5.3)	5 (5.4)	186 (4.1)	55 (0.8)
Unknown	0 (0.0)	0 (0.0)	1 (0.0)	0 (0.0)	0 (0.0)	1 (0.0)	18 (0.3)
<b>Triple Negative Status</b>							
Yes	49 (8.2)	93 (26.5)	299 (10.1)	59 (11.5)	15 (16.3)	515 (11.4)	835 (12.5)
<b>Total Enrolled</b>	599 (13.3)	351 (7.8)	2951 (65.5)	512 (11.4)	92 (2.0)	4505 (100)	
<b>Total Not Enrolled</b>	1443 (21.7)	700 (10.5)	3793 (56.9)	697 (10.5)	32 (0.5)		6665 (100)

\* Race defined Hispanic ethnicity if Hispanic indicator is "yes"

‡ Potential participants identified through electronic pathology reports and medical records who were not enrolled.

§ Body mass index at diagnosis from KPNC electronic records (n=4,413) or self-report (n=91) if electronic data missing

**Table 2. Questionnaire Domains and Data Collection Times, Pathways Study**

Data Domain	Baseline	Follow-up Period (months)						Annual Follow-up*
		6	12	24	48	72	96	
Demographics	x							
Family Health History	x							
Prenatal Exposures	x							
Pregnancy History	x							
Developmental History	x							
Child Health History	x							
Hormone Use	x							
Menstrual History	x	x		x		x		
Body Size Measurements	x	x		x		x		
Smoking	x	x		x		x		
Medications	x	x		x		x		
Physical Activity	x	x		x		x		
Food Frequency Questionnaire	x	x		x		x		
3-Day Food Diary	x	x		x		x		
Vitamins and Supplements	x	x		x		x		
Complementary and Alternative Medicine (CAM)	x	x		x		x		
Organic Foods	x	x		x		x		
Religion and Spirituality	x					x		
SF-12	x					x		
FACT-B	x	x		x				
FACT-Taxane	x	x		x				
MOS (Social Support)	x	x		x		x		
CES-D (Depression)	x							
LOT-R (Optimism)	x							
Interpersonal Processes of Care	x							
Perceived racism	x							
IES-R (PTSD)						x		
Quality of Life - Cancer Survivor Version (QOL-CSV)								x
Sleep Assessment (adapted from PSQI)								x
Memory and concentration (adapted from TICS-30)								x
Physiology of Aging – Functional Status (if age ≥65 y)	x							
Physiology of Aging – Time Get Up and Go (if age ≥65 y)	x							
Neighborhood Characteristics						x		
Lymphedema	x	x		x		x		
Mammography and Breast Exams	x		x	x	x	x	x	x
Medical Conditions/Health Issues (Self-Reported)			x	x	x	x	x	x
Recurrence/New Cancers (Self-Reported)			x	x	x	x	x	x

\* At least one year after 96-month follow-up, assessed at the same time for the whole cohort

Abbreviations: SF-12, 12-item Medical Outcomes Study Short Form Health Study; FACT-B, Functional Assessment of Cancer Therapy – Breast Cancer; MOS, Medical Outcomes Study; CES-D, Center for Epidemiologic Studies Depression Scale; LOT-R, Life Orientation Test – Revised; IES-R, Impact of Events Scale; PTSD, Post-Traumatic Stress Disorder; PSQI, Pittsburgh Sleep Quality Index; TICS-30, Telephone Interview for Cognitive Status

**Table 3. Select Outcomes\* (n, column %) in the Pathways Study Cohort, by Race/Ethnicity, as of November 20, 2020**

	Asian/PI	Black	White	Hispanic	AI/AN	Total
<b>Breast Cancer Recurrence</b>						
Ipsilateral local recurrence	12 (2.0)	9 (2.6)	75 (2.5)	8 (1.6)	1 (1.1)	105 (2.3)
Local/regional recurrence	10 (1.7)	11 (3.1)	40 (1.4)	12 (2.3)	1 (1.1)	74 (1.6)
Distant recurrence	52 (8.7)	42 (12.0)	260 (8.8)	55 (10.7)	14 (15.2)	423 (9.4)
Total	74 (12.4)	63 (17.9)	376 (12.7)	75 (14.6)	16 (17.4)	604 (13.4)
<b>Second Primary Cancer</b>						
Ipsilateral DCIS	1 (0.2)	0 (0.0)	7 (0.2)	1 (0.2)	0 (0.0)	9 (0.2)
Contralateral DCIS	3 (0.5)	1 (0.3)	28 (0.9)	3 (0.6)	0 (0.0)	35 (0.8)
Contralateral Invasive Breast Cancer	13 (2.2)	7 (2.0)	89 (3.0)	13 (2.5)	1 (1.1)	123 (2.7)
Other Invasive (non-breast) Cancer	28 (4.7)	22 (6.3)	215 (7.3)	20 (3.9)	8 (8.7)	293 (6.5)
Total	45 (7.5)	30 (8.5)	339 (11.5)	37 (7.2)	9 (9.8)	460 (10.2)
<b>Deaths</b>						
Breast Cancer	48 (8.0)	58 (16.5)	260 (8.8)	54 (10.5)	12 (13.0)	432 (9.6)
Other Causes	26 (4.3)	41 (11.7)	400 (13.6)	31 (6.1)	13 (14.1)	511 (11.3)
Total	74 (12.4)	99 (28.2)	660 (22.4)	85 (16.6)	25 (27.2)	943 (20.9)
<b>Outcomes for Breast Cancer-free Survival‡</b>	88 (14.7)	80 (22.8)	483 (16.4)	92 (18.0)	19 (20.7)	762 (16.9)
<b>Outcomes for Invasive Disease-Free Survival§</b>	130 (21.7)	126 (35.9)	949 (32.2)	132 (25.8)	34 (37.0)	1371 (30.4)
<b>Any Outcome**</b>	133 (22.2)	126 (35.9)	981 (33.2)	136 (26.6)	34 (37.0)	1410 (31.3)
<b>Total Cohort</b>	599 (100)	351 (100)	2951 (100)	512 (100)	92 (100)	4,505 (100)

\* Recurrences up to date through 8/31/2020; second primary cancers through 12/31/2018; deaths through 12/31/2018

‡ Total recurrence, contralateral second primary invasive breast cancer (excludes new primary DCIS), or breast cancer death

§ Total recurrence, invasive second primary cancer (excludes new primary DCIS), or total deaths

\*\* Breast cancer recurrence, Second primary cancer, or Death from any cause

Abbreviations: AI, American Indian; AN, Alaska Native; DCIS, Ductal Carcinoma In Situ; PI, Pacific Islander